Aller au contenu principal
Retour à l'annuaire
MP
Rhumatologue

Docteur MICHELE POULARD-MARFEUILLE

📍 Villejuif (94)MixteRPPS 10001263796

✨ Profil synthétique

IA · 04/05/2026

Le Docteur Michele Poulard-Marfeuille est rhumatologue à Villejuif. Ses publications sur PubMed couvrent divers aspects de la rhumatologie, notamment les revues générales, l'épidémiologie, les méta-analyses et les recommandations. Ces travaux suggèrent une implication dans la recherche et la pratique clinique.

Expertises présumées

  • Rhumatologie épidémiologique
  • Revue systématique
  • Méta-analyse
  • Élaboration de recommandations
  • Recherche en vie réelle
  • Étude de cas
  • Analyse de registres

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieux de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension

    Circulation. Heart failure · 2025

    📚 8 citations🎯 RCR 3.58
    Lire l'abstract Crossref ↓

    BACKGROUND: Right ventricular functional adaptation to afterload is a major determinant of outcome in pulmonary arterial hypertension (PAH). We aimed to investigate if right ventricular-pulmonary artery (PA) coupling evaluated by the ratio of tricuspid annular plane systolic excursion (TAPSE) to systolic pulmonary artery pressure (sPAP) improves risk assessment scores for survival prediction. METHODS: A total of 677 consecutive patients with PAH (55% idiopathic) were prospectively enrolled with follow-up clinical, right heart catheterization, and echocardiographic evaluations within 12 months (interquartile range, 180–344 days) after initiation of targeted therapies in 11 Italian centers. European Society of Cardiology/European Respiratory Society guidelines-derived risk scores and REVEAL 2.0 (US Registry to Evaluate Early and Long-Term PAH Disease Management 2.0) risk scores were collected at baseline and follow-up. 254 consecutive patients with PAH retrospectively enrolled in a German reference center served as a validation cohort. RESULTS: A low-risk status at a median of 3.7 years (interquartile range, 1.2–6.8) follow-up was significantly associated with each unit (0.1 mm/mm Hg) increase in TAPSE/sPAP under targeted therapies (European Society of Cardiology/European Respiratory Society score: odds ratio, 1.78; P ≤0.001; REVEAL 2.0 score: odds ratio, 1.43; P ≤0.001). At follow-up, the TAPSE/sPAP ratio increased the prognostic information of each risk stratum of the European Society of Cardiology/European Respiratory Society risk score, except the highest risk stratum, with 0.5 mm/mm Hg, 0.35 mm/mm Hg, and 0.30 mm/mm Hg, from the lowest to the intermediate-high risk score, identified as the best cutoff value. TAPSE/sPAP ratio increased the prognostic information of the REVEAL 2.0 score at follow-up, with 0.35 mm/mm Hg identified as the best cutoff value to discriminate within a score of 5 to 8, with no added value for scores <5 and >8. These results were confirmed in the validation cohort. CONCLUSIONS: Assessment of right ventricular-PA coupling by the TAPSE/sPAP ratio in PAH improves risk assessment scores except in the lowest or most advanced stage of the disease

  • 2
    Effectiveness of tezepelumab in severe asthma: A multicenter real-world study

    European journal of internal medicine · 2026

    📚 5 citations🎯 RCR 5.00🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
  • 3
    Internal Phase Separation in Synthetic DNA Condensates

    Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025

    📚 5 citations🎯 RCR 1.87🔓 Open Access📄 PDF gratuit ↗
    Lire l'abstract Crossref ↓

    Abstract Biomolecular condensates regulate cellular biochemistry by organizing enzymes, substrates and metabolites, and often acquire partially de‐mixed states whereby distinct internal domains play functional roles. Despite their physiological relevance, questions remain about the principles underpinning the emergence of multi‐phase condensates. Here, a model system of synthetic DNA nanostructures able to form monophasic or biphasic condensates is presented. Key condensate features, including the degree of interphase mixing and the relative size and spatial arrangement of domains, can be controlled by altering nanostructure stoichiometries. The modular nature of the system facilitates an intuitive understanding of phase behavior, and enables mapping of the experimental phenomenology onto a predictive Flory‐Huggins model. The experimental and theoretical framework introduced is expected to help address open questions on multiphase condensation in biology and aid the design of functional biomolecular condensates in vitro, in synthetic cells, and in living cells.

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal25

▼

Revue générale7

▼

Épidémiologie & registres6

▼

Revue / méta-analyse4

▼

Case report / série3

▼

Recommandations3

▼

Vraie vie / RWE2

▼

Essai clinique1

▼

IRM ostéo-articulaire1

▼

Pédiatrie1

▼

Pharmacovigilance1

▼

Qualité de vie / PROMs1

▼

Santé mentale / fatigue1

▼

SAPL1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.